Home Icon

Loading, Please Wait...

Landos Biopharma to Present at Upcoming Conferences in September

993 Days ago

BLACKSBURG, Va., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Landos Biopharma today announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present at the following conferences in New York:

Event: BioCentury 26th Annual NewsMakers in the Biotech Industry, Sept. 6, 2019 
Location: Millennium Times Square
Date/Time: Friday, Sept. 6, at 9:20 a.m. EDT

Event: H.C. Wainwright 21st Annual Global Investment Conference, Sept. 8-10, 2019
Location: Lotte New York Palace Hotel
Date/Time: Tuesday, Sept. 10, at 3:50 p.m. EDT
Webcast: A live and archived webcast of the presentation will be available at http://wsw.com/webcast/hcw5/lans/.

About Landos Biopharma

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing and has initiated Phase 2 clinical testing of BT-11 for inflammatory bowel disease in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to IND and Phase 1 clinical testing in 2020. Landos is headquartered in Blacksburg, Va. For more information, please visit www.landosbiopharma.com or contact info@landosbiopharma.com or follow us @Landosbio

Chiara Russo (investors)
Solebury Trout

Rich Allan (media)
Solebury Trout

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal